

Yaning Yang

MD PhD

National Cancer Centre, panjiayuan south 17th, Beijing, China

yaning_yang@outlook.com

Education

National Cancer Center, Peking Union Medical College, Tsinghua University

Beijing,

China

PhD in Medical Oncology

Sep. 2021 – Jun. 2024

(expected)

- Thesis title: Clinical strategies for advanced non-small cell lung cancer with *EGFR/ HER2* exon 20 insertions
- supervisor: Prof. Dr. Yan Wang

National Cancer Center, Peking Union Medical College, Tsinghua University

Beijing,

China

MD in Medical Oncology

Sep. 2018 –

Jun. 2021

- Thesis title: Clinical strategies for advanced non-small cell lung cancer with *rare mutation*
- supervisor: Prof. Dr. Yan Wang
- Final grade: 3.4/4

Tongji Medical College, Huazhong University of Science and Technology

Wuhan,

China

Doctor of Medicine

Sep. 2013 – Jun.

2018

- Final grade: 3.4/4, 20/109

Research Interests

Rare mutations in advanced non-small cell lung cancer

- Designing protocol and conducting 2 perspective phase II clinical trials and several prospective studies

Predictive factors of immunotherapy in advanced non-small cell lung cancer patients

- Investigating the predictive roles of Aromatic hydrocarbon receptors and cytokines in advanced non-small cell lung cancer who received immunotherapy

Stipends & Awards

2022 First grade of PhD Award

China

2020 Second grade of MD Award

China

2018 Outstanding graduate Award

China

Research Output

Peer-Reviewed Publications

July 30, 2023

Yaning Yang | Curriculum Vitae

1. **Yang Y**, et al. Immunotherapy as a later-line option for HER2-altered advanced NSCLC: whether taxane is a favorable partner. *Future Oncology* (minor review) (2023)
2. Han SC#, Wang GZ#, **Yang YN**#, Fang WF#, Sun BB#, Zhang JD, Zhou HQ, Zhang L, Wang Y, Zhou GB. Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade. *Signal Transduct Target Ther*. doi: 10.1038/s41392-023-01416-5. (Co-first author) (2023)
3. **Yang Y**, Wang Y. Targeting exon 20 insertion mutations in lung cancer. *Curr Opin Oncol*. doi: 10.1097/CCO.0000000000000919. (2023)
4. **Yang Y**, Ai X, Xu H, Yang G, Yang L, Hao X, Yang K, Mi Y, Wang G, Zhang S, Lei S, Wang Y. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice. *Thorac Cancer*. doi: 10.1111/1759-7714.14684. Epub 2022 Oct 11. (2022)
5. Yang G#, **Yang Y**#, Hu J, Xu H, Zhang S, Wang Y. EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors. *Front Pharmacol*. doi: 10.3389/fphar.2022.984503. (Co-first author) (2022)
6. Yang G#, **Yang Y**#, Liu R#, Li W, Xu H, Hao X, Li J, Zhang S, Xu F, Lei S, Wang Y. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China. *Cancer Med*. doi: 10.1002/cam4.4852. (Co-first author) (2022)
7. Yang G#, **Yang Y**#, Liu R#, Li W, Xu H, Hao X, Li J, Xing P, Zhang S, Ai X, Xu F, Wang Y. First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study. *Ther Adv Med Oncol*. doi: 10.1177/17588359221082339 (Co-first author) (2022)
8. **Yang Y**#, Xu H#, Ma L#, Yang L, Yang G, Zhang S, Ai X, Zhang S, Wang Y. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients. *Cancer Med*. doi: 10.1002/cam4.4336. (2021)
9. **Yang Y**, Yang L, Wang Y. Immunotherapy for Lung Cancer: Mechanisms of Resistance and Response Strategy. *Zhongguo Fei Ai Za Zhi*. doi: 10.3779/j.issn.1009-3419.2021.101.02. (In Chinese) (2021)
10. **Yang Y**, Wang Y. Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors of Small Cell Lung Cancer. *Zhongguo Fei Ai Za Zhi*. doi: 10.3779/j.issn.1009-3419.2020.101.42. (In Chinese) (2020)
11. **Yang Y**, Xu H, Yang G, Yang L, Li J, Wang Y. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib. *Asia Pac J Clin Oncol*. doi: 10.1111/ajco.13284. (2020)

Consortium Publications

1. Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1. *Signal Transduct Target Ther*. doi: 10.1038/s41392-022-01127-3. (2022)
2. Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2). *BMC Med*. doi: 10.1186/s12916-022-02470-6. (2022)
3. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. *BMC Med*. doi: 10.1186/s12916-022-02356-7. (2022)

Conference Contributions

1. **Yang Y**, Liu C, Yang L, Yang G, Xu H, Hao X, Zhang S, Lei S, Wang Y. IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer. ESMO Conference. **Poster**. (2023)
2. **Yang Y**, Yang G, Wang Y. Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study. ASCO Conference. **Poster**. (2023)

3. Han S, **Yang Y**, Gui-Zhen Wang, Wenfeng Fang, Li Zhang, Yan Wang, Guang-Biao Zhou. The expression of aryl hydrocarbon receptor predicts responses to anti-PD-1 antibodies in non-small cell lung cancer. ASCO Conference. **Poster**. (2022)
4. **Yang Y**, Yang G, Xu H, Hao X, Zhang S, Ai X, Lei S, Wang Y. Taxanes plus immunotherapy might be a potential option for HER2-altered NSCLC beyond first-line progression: A retrospective real-world study. Annals of Oncology. ESMO Conference. **Poster**. (2022)
5. **Yang Y**, Wang Y. The Value of Predictive Markers of Progression and Prognosis in ALK-positive patients treated with Crizotinib. Global Academic Conference. **Poster**. (2019)

Clinical trial experience

1. RRx-001 sequentially with a platinum doublet or a platinum doublet in third-Line or beyond in patients with small cell lung cancer (REPLATINUM), a phase III, global multi-center clinical trial. (NCT03699956). **Sub-Investigator**
2. Phase II clinical trial for advanced non-small cell lung cancer harboring HER2 amplification or mutations treated with first-line pyrotinib plus apatinib targeted therapy. (ChiCTR2100052156). **Sub-Investigator**
3. Chidamide combined with sintilimab for advanced and refractory non-small cell lung cancer: an open-label, single-center, single-arm, multi-cohort, phase Ib/II study. (ChiCTR2000034888). **Sub-Investigator**
4. Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811 for Injection in Subjects With Advanced Non-small Cell Lung Cancer Who Have HER2 Expression, Amplification, or Mutation. (NCT04818333). **Sub-Investigator**

Work Experience

National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, China

and Peking Union Medical College

Sep. 2021 – Mar.

2023

Chief resident

Peking Hospital & Cancer Hospital

Beijing,

China

Standardized training of resident physician

Sep. 2018 – Jun. 2021

Qualification certificate for physicians

Sep. 2019

Tongji Hospital

Wuhan, China

Internship

Mar. 2016 – Jun. 2018

Skills

■ **Experimental:** cell culture, transfection, Cas 9, western blot, PCR, flow cytometric analysis, animal surgery, drug injections

■ **Coding:** R language

■ ***Languages:*** Chinese (native), English (fluent, IELTS 7.0)